Clients

Genprex, Inc.

Company Snapshot: Genprex, Inc.

GNPX
Last Change Volume High Low

Company Overview

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Client News

  1. May 19 2022 Genprex to Present at Upcoming Investor Conference in May 2022
  2. May 9 2022 Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference
  3. May 5 2022 Genprex Issues Shareholder Letter and Provides 2022 Corporate Update
  4. Apr 18 2022 Genprex to Participate in Upcoming Investor and Industry Conferences in April 2022